05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for smoking cessation; pharmaceutical preparations for nicotine cessation; pharmaceutical preparations for the treatment of nicotine dependence; pharmaceutical preparations for reducing nicotine cravings; Pharmaceutical preparations for use in discouraging the smoking habit; medicinal preparations for the treatment of nicotine addiction.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for smoking cessation; pharmaceutical preparations for nicotine cessation; pharmaceutical preparations for the treatment of nicotine dependence; pharmaceutical preparations for reducing nicotine cravings; Pharmaceutical preparations for use in discouraging the smoking habit; medicinal preparations for the treatment of nicotine addiction.
The present invention relates to a stabilized composition with significantly improved shelf-life stability. More particularly, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound. The present invention relates also to a use of at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound for the stabilization of a liquid aqueous pharmaceutical composition comprising cytisine.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
The invention relates to 1,2,3′,5′-tetrahydro-2′H-spiro[indole-3,1′-pyrrolo[3,4-c]pyrrole]-2,3′-dione compounds represented by formula (1), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.
The invention relates to 1,2,3′,5′-tetrahydro-2′H-spiro[indole-3,1′-pyrrolo[3,4-c]pyrrole]-2,3′-dione compounds represented by formula (1), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for smoking cessation; pharmaceutical preparations for nicotine cessation; pharmaceutical preparations for the treatment of nicotine dependence; pharmaceutical preparations for reducing nicotine cravings; Pharmaceutical preparations for use in discouraging the smoking habit; medicinal preparations for the treatment of nicotine addiction.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; medical preparations; veterinary preparations; sanitary preparations for medical purposes; Dietetic foods for medicinal purposes; dietetic food adapted for medical use; medicinal preparations and substances; Food for babies and infants; dietary supplements for humans; dietary supplements for animals; Medical wound dressings; disinfectants; preparations for destroying vermin; Pest control preparations and articles; fungicides; herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for nebulisers and inhalers; Substances for nebulisation and inhalation; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Salts and solutions used for inhaled administration, in particular for inhalation and nebulisation.
9.
PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN
A solid pharmaceutical composition comprising amlodipine or its pharmaceutically acceptable salt, in particular amlodipine besylate, ramipril and rosuvastatin or its pharmaceutically acceptable salt, in particular rosuvastatin calcium, in a single dosage unit, a process for its preparation and a single dosage unit comprising it. The composition finds its use in the treatment of cardiovascular diseases.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for the treatment of viral diseases; Antiviral drugs for treating influenza. Inhalers for medical use; Inhalers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for human use; Food supplements; Dietetic substances adapted for medical use; Pharmaceutical preparations for the treatment of viral diseases; Anti-viral agents; none of the afore-mentioned goods in the fields of medical diagnostics, especially laboratory diagnostics, or serology.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; medical preparations; veterinary preparations; sanitary preparations for medical purposes; Dietetic foods for medicinal purposes; dietetic food adapted for medical use; medicinal preparations and substances; Food for babies and infants; dietary supplements for humans; dietary supplements for animals; Medical wound dressings; disinfectants; preparations for destroying vermin; Pest control preparations and articles; fungicides; herbicides.
The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations and substances. Medical apparatus and instruments; Inhalers; Parts and components for medical apparatus and instruments and inhalers.
25.
PHARMACEUTICAL COMPOSITION OF FURAZIDIN FOR VAGINAL ADMINISTRATION
A pharmaceutical composition of furazidin in the form of a vaginal mucoadhesive tablet, said tablet comprising or consisting of: a) a granulate containing furazidin, a pharmaceutically acceptable polymeric mucoadhesive binder, and intragranular pharmaceutically acceptable excipients, said excipients comprising or consisting of one or more intragranular fillers and an intragranular disintegrant; and b) extragranular pharmaceutically acceptable excipients, said excipients comprising or consisting of one or more extragranular fillers, an extragranular disintegrant, and a lubricant, and wherein the tablet comprises from 1 to 15% by weight of furazidin with respect to the weight of the tablet.
The invention relates to a process for the preparation of pharmaceutical oral composition of the active substance dabigatran etexilate and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate in form of hard capsules, and to the said pharmaceutical composition obtainable by the said process.
The present invention relates to a stabilized composition with significantly improved shelf-life stability. More particularly, the present invention relates to a stable liquid aqueous pharmaceutical composition comprising cytisine or a pharmaceutically acceptable salt thereof, at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound. The present invention relates also to a use of at least one antioxidant selected from the group consisting of a sulfite, bisulfite, and metabisulfite compound for the stabilization of a liquid aqueous pharmaceutical composition comprising cytisine.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to an oral fixed-dose immediate release pharmaceutical composition of 2.5 mg of rivaroxaban and 50 mg of acetylsalicylic acid for use in a prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers or for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and/or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 9/24 - Layered or laminated unitary dosage forms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for human use with exclusion of diagnosis kits and diagnostic tests for the identification of susceptibility to coeliac disease and in vitro monitoring of coeliacs.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
The invention relates to a process for the preparation of pharmaceutical oral dosage form of the active substance dabigatran etexilate and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate, the pharmaceutical composition obtainable by said process, to the said pharmaceutical composition obtainable by the said process packed into hard capsules, and to tartaric acid cores as an intermediate for active coats, such as dabigatran etexilate methanesulfonate coat.
The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid harmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.
The present invention relates to fixed dose pharmaceutical compositions in the form of hard capsules comprising Amlodipine, Candesartan cilexetil and Hydrochlorothiazide for the treatment of hypertension.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The present invention relates to a prolonged-release pharmaceutical composition of furazidin for oral administration, which can be used for treating urinary tract infections (UTI). The prolonged-release pharmaceutical composition for oral administration comprises: a) an immediate release component, comprising furazidin and one or more pharmaceutically acceptable excipients; and b) a modified-release component, comprising furazidin, a controlled-release agent, and one or more pharmaceutically acceptable excipients.
The present invention relates to a bilayer tablet for oral administration comprising (1) a first modified release layer comprising tamsulosin or a pharmaceutically acceptable salt thereof and a matrix forming polymer and (2) a second immediate release layer comprising solifenacin or a pharmaceutically acceptable salt thereof and at least one water-insoluble diluent, wherein the tablet is optionally film coated.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cardiovascular preparations; Cardiovascular pharmaceuticals; Pharmaceuticals; Food supplements; Vitamin preparations in the nature of food supplements; Dietetic food preparations adapted for medical use.
The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Lewy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to a bilayer pharmaceutical composition of ramipril and indapamide for oral administration, which can be used for treating hypertension. The pharmaceutical composition comprises: a) an immediate release layer, comprising ramipril, polyvinyl alcohol and one or more pharmaceutically acceptable excipients; and b) a sustained-release layer, comprising indapamide, a sustained-release agent being HPMC or HEC, and one or more pharmaceutically acceptable excipients.
The invention relates to a stable Ramipril granulate and a fixed dose pharmaceutical composition comprising combination of Ramipril and at least one cardiovascular active substance such as Bisoprolol fumarate, Amlodipine and/or Hydrochlorothiazide, wherein incompatibility of active substances is overcome by using a specific excipient with a dual function.
The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid pharmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.
The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid pharmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food supplements; Sanitary preparations for medical purposes; Infant formula; Pharmaceutical preparations and substances; Pharmaceutical preparations for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; Food supplements; Sanitary preparations for medical purposes; Dietetic substances for medicinal use; Infant formula.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances; all the aforesaid excluding products, preparations and/or substances for the prevention and treatment of depression, anxiety, psychosis, schizophrenia, dementia and/or the Alzheimer’s disease.
The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to 1,2,3′,5′-tetrahydro-2′H-spiro[indole-3,1′-pyrrolo[3,4-c]pyrrole]-2,3′-dione compounds represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention relates to a solid pharmaceutical composition of cytisine for oral administration in the form of a granulate obtained by wet-granulation comprising cytisine, a binder and a porous carrier carrier free of lactose and microcrystalline cellulose, and a method for the preparation of the granulate.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
The present invention relates to a pharmaceutical composition comprising a granulate comprising brexpiprazole, wherein the granulate is obtained by wet-granulation of a carrier using a granulation liquid that is a solution of brexpiprazole in a solvent system. The present invention relates also to a granulate used in the pharmaceutical composition, and a unit dosage form comprising the pharmaceutical composition, and the method for manufacturing a pharmaceutical composition comprising brexpiprazole.
The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazolesrepresented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consistingof Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia- related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
87.
A PHARMACEUTICAL COMPOSITION COMPRISING METAMIZOLE, DROTAVERINE, AND CAFFEINE
The present inventions relates to a pharmaceutical composition comprising, in one dosage form, metamizole, drotaverine, and caffeine, in which metamizole in the said composition is present in the form of a granulate comprising metamizole, and drotaverine and caffeine are present outside the said granulate. The present inventions relates also to a granulate comprising metamizole and a granulate comprising drotaverine, as well as their use.
The invention relates to 1,2,3',5'- tetrahydro- 2?- spiropndole- 3,1 '- pyrrolo[3,4- c]pyrrole]- 2,3'- dione compounds represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The invention relates to 1,2,3',5'- tetrahydro- 2Ή- spiropndole- 3,1 '- pyrrolo[3,4- c]pyrrole]- 2,3'- dione compounds represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of cancer, immune diseases, inflammatory conditions, allergic skin diseases associated with excessive proliferation, blinding disease and viral infections.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The invention relates to a tablet comprising 5 to 20 %wt. ezetimibe, 5 to 20 %wt. plastic excipient, 3 to 10 %wt. disintegrant, 1 to 12 %wt. starch, 0.5 to 1.5 %wt. silica, 0.5 to 2.5 %wt. stearic acid, wherein a weight ratio stearic acid to silica is 1:1 to 3:1, and wherein the tablet comprises a further diluent and binder, and optionally surfactant.
The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention relates to the field of therapeutic recombinant fusion proteins. Specifically, the invention relates to fusion proteins of Pseudomonas exotoxin A in combination with a human oncostatin M (OSM) fragment or a mutant form of an oncostatin M fragment, to a mutant form of an oncostatin M fragment, and to the use thereof in antineoplastic therapy.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
